跳至主要内容
临床试验/NCT01630655
NCT01630655已完成1 期

An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fasting Condition

Torrent Pharmaceuticals Limited1 个研究点 分布在 1 个国家开始时间: 2012年6月28日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
试验地点
1
主要终点
bioequivalence based on Composite of Pharmacokinetics

研究概览

简要总结

Objective:

Primary objective of the present study was to compare the single dose bioavailability of Torrent's Felodipine Extended-Release Tablets USP 10 mg and Innovator's (Mylan Pharmaceuticals Inc., USA) Felodipine Extended-Release Tablets USP 10 mg. Dosing periods were separated by a washout period of 17 days during fasting study.

Study Design:

Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy males within the age range of 18 to 50 years.
  • A body mass index within 18-25 Kg/m
  • Given written informed consent to participate in the study.
  • Absence of diseases markers of HIV 1 & 2, Hepatitis B & C virus and RPR.
  • Absence of significant disease or clinically significant abnormal laboratory
  • values on laboratory evaluation, medical history and physical examination during the screening.
  • A normal 12-lead ECG.
  • A normal chest X-Ray.
  • Comprehension of the nature and purpose of the study and compliance with the requirements of the entire protocol.
  • No history or no evidence of hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.
  • No history of allergic rash.
  • No history of significant systemic diseases.
  • No history of psychiatric disorders or addiction to any recreational drug or drug dependence.
  • No donation of blood within 56 days prior to study check-in.
  • No participation in any clinical study within the past 56 days.
  • No receipt of any prescription drugs or OTC products, with in two weeks prior to study check-in.
  • No history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in.
  • No family history of neurological disorders.
  • Not consumed alcohol and xanthine containing food and beverages, cigarettes and tobacco products, for at-list 48 hours, prior to study check-in.
  • Negative results for drugs of abuse in urine and alcohol breath analysis during check-in of each period.
  • Not consumed grape fruit juice within the 48 hours prior to study check-in.

排除标准

  • Blood pressure Systolic> 140 mm Hg and < 110 mm Hg Diastolic< 70 mm Hg > 90 mm Hg
  • History of seizures
  • History of alcohol consumption for more than 2 units/day.
  • High caffeine or tobacco consumption
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • Any unusual or abnormal diet, for whatever reason e.g. fasting due to religious reasons.
  • Used any pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study

结局指标

主要结局

bioequivalence based on Composite of Pharmacokinetics

bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验